Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera ...

The therapy targets mast cells by inhibiting receptor tyrosine kinase KIT, crucial for mast cell function and survival. Significant improvements in UAS7 and quality of life were observed.

The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

The epidermal growth factor receptor (EGFR) is a target found in high concentrations in several solid tumors including lung, breast, colorectal, and brain. Tyrosine kinase inhibitors, such as ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Intas Pharmaceuticals has received approval from the Subject Expert Committee (SEC), functioning under the Central Drugs ...

Illumina is expanding access to its oncology range of in vitro diagnostic (IVD) tests, as the company's TruSight Oncology (TSO) Comprehensive IVD is now covered under Medicare. This coverage also ...